Abstracts tagged "remission"

Abstract Number: 441 • 2015 ACR/ARHP Annual Meeting
Ultrasound Assessment of Early Response to Certolizumab Pegol Can Predict Future Response in Patients with Rheumatoid Arthritis
Takanori Fujimura, Takashi Fujimoto, Ryota Hara, Naoki Shimmyo, Yasunori Kobata, Akira Kido, Yasuhiro Akai and Yasuhito Tanaka, The Center for Rheumatic Diseases, Nara Medical University, Kashihara, Japan
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fab’ fragment of a humanized anti-TNF antibody with high affinity to TNF. It brings rapid improvement of the…
Abstract Number: 492 • 2015 ACR/ARHP Annual Meeting
Correlations Between Clinical, Laboratory and Ultrasound Joint Examination in RA Patients Treated with Rituximab
Andreea Borangiu¹, Diana Mazilu¹, Ioana Saulescu¹, Evelina Iachim², Laura Grosanu¹, Cosmin Constantinescu¹, Andra Balanescu¹, Denisa Predeteanu¹, Ruxandra Ionescu¹ and Daniela Opris¹, ¹University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Carol Davila Medicine and Pharmacy University, Bucharest, Romania
Background/Purpose: Correct assessment to biologics in rheumatoid arthritis (RA) patients is extremely important regarding future patient management. There is still an open debate about the…
Abstract Number: 516 • 2015 ACR/ARHP Annual Meeting
Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?
Hanna Gul¹, Maria Jesus Isorna Porto², Elizabeth M.A. Hensor³, Frederique Ponchel⁴, Richard J. Wakefield⁵ and Paul Emery⁶, ¹Rheumatology, Leeds Institute of Rheumatology and Musculoskeletal Medicine, Leeds, United Kingdom, ²Internal Medicine, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Remission is the key treatment goal in rheumatoid arthritis (RA). Although clinical remission is increasingly achieved, many patients progress both structurally and functionally. We…
Abstract Number: 588 • 2015 ACR/ARHP Annual Meeting
Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance
Jun Kikuchi, Akiko Shibata, Ryota Sakai, Kentaro Chino, Tsuneo Kondo, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Tocilizumab (TCZ) is clinically effective against rheumatoid arthritis (RA) and over 50% of RA patients who had completed 5 years of TCZ treatment maintained…
Abstract Number: 600 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Disease Activity in Rheumatoid Arthritis
Virginia Ruiz-Esquide¹, Pascal Zufferey², Jose Inciarte-Mundo¹, Jordi Yagüe³, M. Victoria Hernández⁴, Julio Ramirez¹, Jeanne Berner², Mariona Pascal³, Andrea Cuervo¹, Juan D. Cañete⁵ and Raimon Sanmarti^1,6, ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³Immunology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Hospital Clínic i Provincial, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁶Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6R monoclonal antibody approved for the treatment of active rheumatoid arthritis (RA) (EMA: 8mg/kg q4w). Response to treatment may…
Abstract Number: 601 • 2015 ACR/ARHP Annual Meeting
Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A within Randomized Control Trial Based Cost-Utility Analysis
Antoine Vanier¹, Florence Tubach², Toni Alfaiate³, Xavier Mariette⁴ and Bruno Fautrel⁵, ¹Biostatistics, Public Health and Medical Informatics, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6, Paris, France, ²Epidemiology and Clinical Research, AP-HP Bichat Hospital / University of Paris-Diderot / INSERM CIC-EC 1425, Paris, France, ³Epidemiology and Clinical Research, AP-HP Bichat Hospital / INSERM CIC-EC 1425, Paris, France, ⁴Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁵Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France
Background/Purpose: Once remission is achieved for patients with rheumatoid arthritis (RA), treatment down-titration should be attempted, for safety issues or economic reasons. One of the…
Abstract Number: 1319 • 2015 ACR/ARHP Annual Meeting
18F-Fluorodeoxyglucose Positron Emission Computer Tomography and Ultrasonography for Assessing Remission in Patients with Rheumatoid Arthritis
Charline Rinkin¹, Pacôme Fosse², Nathalie Chapelier¹, Laurence Seidel³, Adelin Albert³, Roland Hustinx⁴ and Michel Malaise¹, ¹Rheumatology Department, CHU of Liège, Liège, Belgium, ²Nuclear Medicine Department, CHU of Angers, Angers, France, ³Biostatistic Department, CHU of Liège, Liège, Belgium, ⁴Nuclear Medicine Department, CHU of Liège, Liège, Belgium
Background/Purpose: The disease activity score based on 28 joints (DAS-28) might not be sufficient to assess remission in rheumatoid arthritis (RA). Several studies have shown…
Abstract Number: 2591 • 2015 ACR/ARHP Annual Meeting
Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients
Pascal Zufferey¹, Myriam Riek², Giorgio Tamborrini³, Laure Brulhart⁴, Martin Toniolo⁵, Sandra Blumhardt⁶, Burkhard Moeller^7,8 and Hans Ruedi Ziswiler⁹, ¹Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ²SCQM Registry, Zurich, Switzerland, ³Rheumatologie, Bethesda spital, Basel, Switzerland, ⁴médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁵Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁶rheumatology, USZ, zurich, Switzerland, ⁷Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁸Rheumatology, Inselspital University Hospital, Bern, Switzerland, ⁹Osteorheuma, Bern, Switzerland
Background/Purpose: Previous publications have suggested that patients in clinical remission with residual ultrasound (US) synovitis flare more often and do not stay in remission as…
Abstract Number: 2594 • 2015 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy
Femke Lamers-Karnebeek¹, Marjan Ghiti Moghadam², Harald E. Vonkeman³, Janneke Tekstra⁴, Annemarie Schilder⁵, Henk Visser⁶, Peter M. ten Klooster⁷, Eric H. Sasso⁸, David Chernoff⁹, Willem Lems¹⁰, Dirkjan van Schaardenburg¹¹, Robert Landewé¹², Iet Van Albada¹³, T.R.D.J. Radstake¹⁴, Piet van Riel¹⁵, Mart A.F.J. van de Laar¹⁶ and Tim Jansen¹⁷, ¹Rheumatology, Radboudumc, Nijmegen, Netherlands, ²rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ⁴Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, ⁶Rheumatology, Alysis Care Group, Arnhem, Netherlands, ⁷Pcgr, University of Twente, Enschede, Netherlands, ⁸Crescendo Bioscience Inc., South San Francisco, CA, ⁹Crescendo Bioscience, Inc., South San Francisco, CA, ¹⁰Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Department of Rheumatology, Amsterdam, Netherlands, ¹¹Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands, ¹²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ¹³Meander MC, Amersfoort, Netherlands, ¹⁴Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁵Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ¹⁷VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: Prediction which rheumatoid arthritis (RA) patients in low disease activity (LDA) can successfully discontinue TNF inhibition (TNFi) may improve the cost-effectiveness of RA management.…
Abstract Number: 2674 • 2015 ACR/ARHP Annual Meeting
Patient Global Assessment in Evaluating Boolean-Based Remission in Rheumatoid Arthritis-Is It Really Required Instead of Physician Global Assessment? a Comparative Study with Ultrasound
Gulsen Ozen¹, Ali Ugur Unal¹, Atakan Topcu², Pamir Atagunduz¹, Haner Direskeneli¹ and Nevsun Inanc¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Patient global assessment (PtGA) is included in all the current remission definitions for RA despite the fact that PtGA is not exclusively related to…
Abstract Number: 45 • 2015 ACR/ARHP Annual Meeting
Contributions of Social Determinants of Health on Probability of Remission in Early and Established Rheumatoid Arthritis Patients
Kangping Cui^1,2, Claire Bombardier^3,4,5, George A. Tomlinson^6,7,8 and the OBRI Investigators, ¹Toronto General Hospital Research Institute - University Health Network, Toronto, ON, Canada, ²Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁷Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁸Medicine, University Health Network, Toronto, ON, Canada
Background/Purpose: Treatment responses and outcomes vary among rheumatoid arthritis (RA) patients. There is limited evidence on the contribution of social determinants of health (SDH) to…
Abstract Number: 2686 • 2015 ACR/ARHP Annual Meeting
No Clear Association Between the Presence of Ultrasound Synovitis and Patient Reported Outcomes in Rheumatoid Arthritis Patients in Remission
Myrthe van der Ven¹, T. Martijn Kuijper¹, Andreas Gerards², I. Tchetverikov³, A.E.a.M. Weel^1,4, Derkjen van Zeben⁵, Mieke Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ³Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁴Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands
Background/Purpose: Several studies assessed disease activity with ultrasound in rheumatoid arthritis (RA) patients who were in clinical remission. These studies found ultrasound synovitis in 48-73%…
Abstract Number: 155 • 2015 ACR/ARHP Annual Meeting
Absence of Clinical and Ultrasound Activity of Hand and Foot: Is That Possible?: Experience in an Argentinian Rheumatoid Arthritis Cohort
María Victoria Martire¹, Gloria Crespo², Diego Puente Trigo², Vanesa Duarte², Maritza Manzano², Leandro Carlevaris Sr.², Anastasia Secco², Lida Santiago², Marta Mamani² and Lucila Marino Claverie², ¹Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ²Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina
Background/Purpose: Currently, one of the main goals of rheumatoid arthritis (RA) treatment is to attain remission. Stricter criteria as CDAI, SDAI ACR/ EULAR Boolean have…
Abstract Number: 2732 • 2015 ACR/ARHP Annual Meeting
The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective
Norman B. Gaylis¹, Steven Needell² and Joanne Sagliani¹, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Boca Radiology Group, Boca Raton, FL
Background/Purpose: Although adrenocorticotropin (ACTH) gel was approved by the FDA for the treatment of RA in 1952, data on its clinical and structural benefits for…
Abstract Number: 157 • 2015 ACR/ARHP Annual Meeting
Agreement Between DAS28, ACR/EULAR, SDAI, CDAI and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care
Cecilie Heegaard Brahe¹, Lene Terslev², Simon Krabbe³, Mikkel Østergaard⁴, Henrik Rogind⁵, Hanne Jensen⁶, Annette Hansen⁷, Jesper Nørregaard⁸, Søren Jacobsen⁹, Karen Ellegaard¹⁰, Viktoria Fana¹, Lars Juul⁷, Tuan K. Huynh⁸, Dorte V. Jensen⁷, Natalia Manilo⁶, Karsten Heller Asmussen⁶, Per Brown-Frandsen⁹, Søren Tobias Torp-Pedersen¹¹, Niels Steen Krogh¹² and Merete Lund Hetland², ¹Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ³Center for Rheumatology and Spine diseases, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁴Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵Center for Rheumatology and Spine Diseases, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁶Department of Rheumatology, Copenhagen University Hospital at Frederiksberg-Bispebjerg, Denmark, Frederiksberg, Denmark, ⁷Department of Rheumatology, Copenhagen University Hospital at Gentofte - Herlev, Denmark, Gentofte, Denmark, ⁸Department of Rheumatology, Copenhagen University Hospital at Nordsjælland, Denmark, Hillerød, Denmark, ⁹Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ¹⁰Department of rheumatology, Frederiksberg-Bispebjerg Hospital, The Parker Institute, Copenhagen, Denmark, ¹¹Department of Radiology, Copenhagen University Hospital at Glostrup, Denmark, Glostrup, Denmark, ¹²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: Different remission criteria are available for patients with rheumatoid arthritis (RA). None of the criteria includes imaging remission, even though studies have shown that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].